Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17051109 | 0.85 | POLB (0.36) | POLBCYP1A2GAAGRM5SSTR4 | |
| SCHEMBL20866435 | 0.81 | SSTR4 (0.33) | POLBCYP1A2GAAGRM5SSTR4 | |
| SCHEMBL24249763 | 0.81 | RAB9A (0.33) | POLBCYP1A2GAAGRM5SSTR4 | |
| SCHEMBL15730560 | 0.79 | SSTR4 (0.35) | POLBCYP1A2GAAGRM5SSTR4 | |
| SCHEMBL19176830 | 0.79 | RAB9A (0.33) | POLBCYP1A2GAAGRM5SSTR4 | |
| SCHEMBL22593916 | 0.75 | RAB9A (0.34) | POLBCYP1A2MAPTBRD4LMNA | |
| SCHEMBL20430541 | 0.75 | POLB (0.37) | POLBCYP1A2GAAGRM5SSTR4 | |
| SCHEMBL20866495 | 0.73 | RAB9A (0.36) | POLBCYP1A2MAPTLMNA | |
| SCHEMBL17045335 | 0.72 | POLB (0.38) | POLBCYP1A2GAAGRM5SSTR4 | |
| SCHEMBL14752431 | 0.72 | PARP1 (0.42) | POLBCYP1A2GAAGRM5SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | WDR5, MLLT1, WDR1 | POLB 3071/4885CYP1A2 4670/4885GAA 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.